In a patient with metastatic colorectal cancer, researchers found tumor-infiltrating lymphocytes that targeted KRAS G12D with TCRs that were confined to HLA-C*08:02. This patient’s metastatic pancreatic cancer objectively regressed after receiving TCR gene therapy that targeted the KRASG12D driving mutation. Here, KRAS is linked to neoplasm.